XCath CEO Eduardo Fonseca Highlights Potential for Telesurgery at Inaugural SRS Telesurgery Consensus Conference

Panel addressed modern clinical cases for remote surgery and its impact on vascular crises

HOUSTON--(BUSINESS WIRE)--XCath, an early-stage medical device company dedicated to expanding endovascular treatment modalities through its robotic systems and guidewires, took part in a panel last week at the first-ever Telesurgery Consensus Conference hosted by the Society of Robotic Surgery (SRS). The event, which took place in Orlando, Florida from February 3-4, provided a forum for international leaders in the surgical and robotic spaces to examine priorities and challenges in the ever-changing field of remote surgery.

XCath’s Chief Executive Officer, Eduardo Fonseca, participated in an industry panel titled, “Current clinical cases for telesurgery: If we had telesurgery today how would it change vascular emergency events.” Topics of discussion ranged from present telesurgery applications to treatment implications related to urgent vascular occurrences.

“The SRS Telesurgery Consensus Conference was the perfect forum for XCath to debut its innovative approach,” said Dr. Frederic H. Moll, Founder of Intuitive Surgical and Auris Health. “Implementing modern technologies, like robotics, can improve both treatment precision and access to endovascular care, and I look forward to continue contributing to XCath’s advancements to the medical device landscape.”

For more information about the SRS Telesurgery Consensus Conference, visit https://srobotics.org/. To learn more about XCath, visit https://www.xcath.com/

About XCath

Founded in 2017, XCath is a dynamic startup at the cutting edge of revolutionary medical robotics, nanorobotics and materials science. XCath develops next-generation endovascular robotic systems and steerable guidewires to treat life-threatening conditions like cerebrovascular disorders. With strategically located campuses in Houston, Texas – home to the world's largest medical center – and Pangyo, South Korea, often referred to as the Silicon Valley of Korea, XCath is committed to bringing its innovative solutions to patients around the world.